ABEOME CORPORATION — Department of Health and Human Services SBIR Phase II: NHLBI
ABEOME CORPORATION — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,482,472
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NHLBI
- Solicitation
- PA14-071
- NAICS
- —
- Place of performance
- GA
- Period
- 2016-09-19 → 2018-08-31
Description
DESCRIPTION provided by applicant We have developed and completed a proof of principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to PCSK injection and have identified a set of high affinity neutralizing antibodies which will be tested in animals for efficacy and potency PUBLIC HEALTH RELEVANCE Therapeutic and diagnostic applications of monoclonal antibodies mAbs offer a way to target treatments to specific proteins However monoclonal antibodies have traditionally been made using hybridoma technologies which only access a small fraction of the immune system Abeome has developed a novel method of antibody discovery using direct sorting of antigen specific antibody producing cells Thus the immediate goal for this Phase project is to test and improve Abeomeandapos s newly discovered antibodies that neutralize the PCSK LDLR interaction in animals to determine their efficacy and potency Our ultimate goal is to develop an immuno therapeutic for the treatment of hypercholesterolemia and to partner the technology with pharmaceutical biotechnology companies